Impact of lesion calcification on angiographic outcomes after Absorb everolimus-eluting bioresorbable vascular scaffold implantation: an observation from the ABSORB Japan trial.
OBJECTIVE
We aimed to investigate the impact of lesion calcification on angiographic outcomes after Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in comparison with those after cobalt-chromium everolimus-eluting stent (CoCr-EES) implantation.


RESULTS
The present post hoc analysis of the ABSORB Japan randomised trial compared post-procedure and 13-month angiographic outcomes between patients implanted with BVS and CoCr-EES based on the presence or absence of calcification, excluding extremely heavily calcified lesions or lesions requiring rotational atherectomy. The study population comprised 384 patients with 384 lesions (including 114 lesions [29.7%] with moderate or severe calcification), classified into two subgroups: calcification, 114 (BVS: n=72 and CoCr-EES: n=42) and non-calcification, 270 (BVS: n=181 and CoCr-EES: n=89). Follow-up angiography was performed in 94.8% of patients. Both post-procedure and follow-up in-device minimal lumen diameters were comparable in both the BVS arm (calcification vs. non-calcification: 2.43±0.32 mm vs. 2.43±0.39 mm, p=0.91 and 2.17±0.49 mm vs. 2.27±0.47 mm, p=0.17) and in the CoCr-EES arm (2.68±0.34 mm vs. 2.65±0.42 mm, p=0.62 and 2.57±0.52 mm vs. 2.47±0.53 mm, p=0.36).


CONCLUSIONS
Moderate or severe lesion calcification (excluding patients with extremely heavily calcified lesions or lesions requiring rotational atherectomy) does not negatively affect angiographic outcomes at both post-procedure and 13-month follow-up after BVS implantation.
Kurashiki Central Hospital, Kurashiki, Japan.
Masanobu
M
Ohya
Kazushige
K
Kadota
Yohei
Y
Sotomi
Ken
K
Kozuma
Kengo
K
Tanabe
Masaaki
M
Uematsu
Tomohiro
T
Kawasaki
Yoshihiro
Y
Morino
Tetsuya
T
Tobaru
Koichi
K
Nakao
Kouichi
K
Tachibana
Koichi
K
Kishi
Yoshisato
Y
Shibata
Shihwa
S
Ying
Hajime
H
Kusano
Gregg W
GW
Stone
Jeffery J
JJ
Popma
Yoshinobu
Y
Onuma
Patrick W
PW
Serruys
Takeshi
T
Kimura
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020341:Absorbable Implants / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000628:therapy; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage / Q000627:therapeutic use; D007564:Japan; D009203:Myocardial Infarction / Q000628:therapy; D062645:Percutaneous Coronary Intervention / Q000379:methods; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D061205:Vascular Calcification / Q000150:complications
D002317:Cardiovascular Agents; D000068338:Everolimus; D020123:Sirolimus